Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Vinod SK, Hau E (2020) Radiotherapy treatment for lung cancer: current status and future directions. Respirol 25 Suppl 2:61–71. https://doi.org/10.1111/resp.13870

Article  Google Scholar 

Césaire M, Montanari J, Curcio H, Lerouge D, Gervais R, Demontrond P et al (2022) Radioresistance of non-small cell lung cancers and therapeutic perspectives. Cancers (Basel). https://doi.org/10.3390/cancers14122829

Article  PubMed  Google Scholar 

Yoon SM, Shaikh T, Hallman M (2017) Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 8(1):1–20. https://doi.org/10.5306/wjco.v8.i1.1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE et al (2020) Long-term results of NRG Oncology RTOG 0617: standard- Versus High-Dose Chemoradiotherapy with or without Cetuximab for Unresectable Stage III Non-small-cell Lung Cancer. J Clin Oncol 38(7):706–714. https://doi.org/10.1200/jco.19.01162

Article  CAS  PubMed  Google Scholar 

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F et al (2023) Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol 18(2):181–193. https://doi.org/10.1016/j.jtho.2022.10.003

Article  CAS  PubMed  Google Scholar 

Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF et al (2021) Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol 16(5):860–867. https://doi.org/10.1016/j.jtho.2020.12.015

Article  CAS  PubMed  Google Scholar 

Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199. https://doi.org/10.1016/s1470-2045(14)71207-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y et al (2017) Cardiac toxicity after Radiotherapy for Stage III Non-small-cell Lung Cancer: pooled analysis of dose-escalation trials delivering 70 to 90 gy. J Clin Oncol 35(13):1387–1394. https://doi.org/10.1200/jco.2016.70.0229

Article  PubMed  PubMed Central  Google Scholar 

Wardman P (2007) Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 19(6):397–417. https://doi.org/10.1016/j.clon.2007.03.010

Article  CAS  PubMed  Google Scholar 

Rosenberg A, Knox S (2006) Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys 64(2):343–354. https://doi.org/10.1016/j.ijrobp.2005.10.013

Article  CAS  PubMed  Google Scholar 

Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6(10):757–764. https://doi.org/10.1016/s1470-2045(05)70292-8

Article  CAS  PubMed  Google Scholar 

Urtasun RC, Chapman JD, Feldstein ML, Band RP, Rabin HR, Wilson AF et al (1978) Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl 3:271–275

CAS  PubMed  PubMed Central  Google Scholar 

Toulany M, Mihatsch J, Holler M, Chaachouay H, Rodemann HP (2014) Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition. Radiother Oncol 111(2):228–236. https://doi.org/10.1016/j.radonc.2014.04.001

Article  CAS  PubMed  Google Scholar 

Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ et al (2023) Dose-limiting pulmonary toxicity in a phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for patients with stage 3 Unresectable Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 116(4):837–848. https://doi.org/10.1016/j.ijrobp.2023.01.006

Article  PubMed  Google Scholar 

Hoffner B, Leighl NB, Davies M (2020) Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Cancer Treat Rev 85:101979. https://doi.org/10.1016/j.ctrv.2020.101979

Article  CAS  PubMed  Google Scholar 

Akdeniz N, Küçüköner M, Kaplan MA, Urakçı Z, Karhan O, Sezgin Y et al (2020) Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer. Int J Clin Oncol 25(12):2015–2024. https://doi.org/10.1007/s10147-020-01767-x

Article  CAS  PubMed  Google Scholar 

Scott CL, Swisher EM, Kaufmann SH (2015) Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 33(12):1397–1406. https://doi.org/10.1200/jco.2014.58.8848

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G et al (2017) Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 8(40):69105–69124. https://doi.org/10.18632/oncotarget.19079

Article  PubMed  PubMed Central  Google Scholar 

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895–903. https://doi.org/10.1016/s1470-2045(17)30380-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(1):e15–e28. https://doi.org/10.1016/s1470-2045(18)30786-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Georgieva M, da Silveira Nogueira Lima JP, Aguiar P Jr., de Lima Lopes G Jr., Haaland B (2018) Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. Lung Cancer 124:248–254. https://doi.org/10.1016/j.lungcan.2018.08.018

Article  PubMed  Google Scholar 

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P (2019) Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (> 50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer 127:44–52. https://doi.org/10.1016/j.lungcan.2018.11.008

Article  PubMed  Google Scholar 

Kuo WT, Tsai YC, Wu HC, Ho YJ, Chen YS, Yao CH, Yao CH (2015) Radiosensitization of non-small cell lung cancer by kaempferol. Oncol Rep 34(5):2351–2356. https://doi.org/10.3892/or.2015.4204

Article  CAS  PubMed  Google Scholar 

Komorowska D, Radzik T, Kalenik S, Rodacka A (2022) Natural radiosensitizers in radiotherapy: cancer treatment by combining ionizing radiation with resveratrol. Int J Mol Sci. https://doi.org/10.3390/ijms231810627

Article  PubMed  PubMed Central  Google Scholar 

Afzal O, Kumar S, Haider MR, Ali MR, Kumar R, Jaggi M, Bawa S (2015) A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem 97:871–910. https://doi.org/10.1016/j.ejmech.2014.07.044